

**On-line Table: Comparison of clinical findings and outcomes between the Solitaire stent group and other stent group**

|                                              | Solitaire<br>Group (n = 13) | Other Stent<br>Group (n = 14) | P Value           |
|----------------------------------------------|-----------------------------|-------------------------------|-------------------|
| Age (median) (IQR)                           | 69 (55.5–75.0)              | 68.5 (64.8–81.0)              | .458              |
| Sex (male/female) (%)                        | 8:5 (61.5/38.5)             | 7:7 (50.0/50.0)               | .547              |
| Location (1) (No.) (%)                       |                             |                               | 1.000             |
| Anterior circulation                         | 11 (84.6)                   | 12 (85.7)                     |                   |
| Posterior circulation                        | 2 (15.4)                    | 2 (14.3)                      |                   |
| Location (2) (No.) (%)                       |                             |                               | .124              |
| ICA (intracranial)                           | 2 (15.4)                    | 8 (57.1)                      |                   |
| MCA M1                                       | 8 (61.5)                    | 4 (28.6)                      |                   |
| MCA M2                                       | 1 (7.7)                     | 0                             |                   |
| BA                                           | 1 (7.7)                     | 2 (14.3)                      |                   |
| VA                                           | 1 (7.7)                     | 0                             |                   |
| Comorbidities (No.) (%)                      |                             |                               |                   |
| Hypertension                                 | 6 (46.2)                    | 8 (57.1)                      | .568              |
| Diabetes mellitus                            | 5 (38.5)                    | 3 (21.4)                      | .420              |
| Atrial fibrillation                          | 4 (30.8)                    | 8 (57.1)                      | .252              |
| Hyperlipidemia                               | 5 (38.5)                    | 2 (14.3)                      | .209              |
| Coronary artery disease                      | 1 (7.7)                     | 1 (7.1)                       | 1.000             |
| Smoking                                      | 2 (15.4)                    | 4 (28.6)                      | .648              |
| Cancer                                       | 5 (38.5)                    | 1 (7.1)                       | .077              |
| TOAST (No.) (%)                              |                             |                               | .162              |
| LAA                                          | 5 (38.5)                    | 4 (28.6)                      |                   |
| CE                                           | 3 (23.1)                    | 8 (57.1)                      |                   |
| SUD                                          | 5 (38.5)                    | 2 (14.3)                      |                   |
| IV thrombolysis (yes) (%)                    | 4/9 (30.8)                  | 5/9 (35.7)                    | 1.000             |
| Admission NIHSS (median) (IQR)               | 16.0 (8.5–20.5)             | 15.5 (10.5–20.5)              | .923              |
| After IAT NIHSS (median) (IQR)               | 9.0 (4.0–20.0)              | 16.5 (6.8–23.0)               | .458              |
| Discharge NIHSS (median) (IQR)               | 9.0 (2.5–24.0)              | 16.5 (3.0–28.5)               | .526              |
| mRS at discharge (median) (IQR)              | 4.0 (2.0–5.0)               | 5.0 (2.8–5.3)                 | .440              |
| mRS at discharge 0–2 (%)                     | 4 (30.8)                    | 3 (21.4)                      | .678              |
| mRS at 3 mo (median) (IQR)                   | 3.0 (1.5–5.5)               | 4.0 (2.8–6.0)                 | .445              |
| mRS at 3 mo 0–2 (%)                          | 5 (38.5)                    | 3 (21.4)                      | .420              |
| mRS at 6 mo (median) (IQR)                   | 2.0 (0.5–6.0)               | 5.0 (2.0–6.0)                 | .334              |
| mRS at 6 mo 0–2 (%)                          | 7 (53.8)                    | 4 (28.6)                      | .252              |
| mRS at 12 mo (median) (IQR)                  | 2.0 (0–6.0)                 | 5.0 (1.8–6.0)                 | .298              |
| mRS at 12 mo 0–2 (%)                         | 7 (53.8)                    | 4 (28.6)                      | .252              |
| Time to emergency department (min)           | 250                         | 159                           | .923              |
| Median (IQR) (min)                           | (116.5–340.0)               | (36.0–481.8)                  |                   |
| Time to angiography (min)                    | 313                         | 300                           | .903              |
| Median (IQR) (min)                           | (187.5–434.0)               | (134.5–605.0)                 |                   |
| Time to reperfusion (min)                    | 375                         | 419                           | .593              |
| Median (IQR) (min)                           | (286.5–473.5)               | (269.3–700.8)                 |                   |
| Procedure time (min)                         | 69                          | 115                           | .022 <sup>a</sup> |
| Median (IQR) (min)                           | (37.5–121.5)                | (76.3–175.5)                  |                   |
| GP IIb/IIIa inhibitors (yes) (%)             | 7/6 (53.8)                  | 11/3 (78.6)                   | .236              |
| Postprocedural mTICI grade (0–2a/2b–3) (%)   | 2/11 (15.4/84.6)            | 3/11 (21.4/78.6)              | 1.000             |
| ISR at discharge (yes) (%)                   | 2/9 (18.2)                  | 1/10 (9.9)                    | 1.000             |
| ISR at 3 mo (yes) (%)                        | 2/5 (28.6)                  | 4/5 (44.4)                    | .633              |
| Overall hemorrhagic transformation (yes) (%) | 2/11 (15.4)                 | 5/9 (35.7)                    | .385              |
| Symptomatic ICH (yes) (%)                    | 0/13 (0)                    | 3/11 (21.4)                   | .222              |
| Mortality at 3 mo (No.) (%)                  | 3 (23.1)                    | 4 (28.6)                      | 1.000             |
| Mortality at 6 mo (No.) (%)                  | 4 (30.8)                    | 4 (28.6)                      | 1.000             |
| Mortality at 12 mo (No.) (%)                 | 4 (30.8)                    | 4 (28.6)                      | 1.000             |

**Note:**—IQR indicates interquartile range; BA, basilar artery; VA, vertebral artery; LAA, large-artery atherosclerosis; CE, cardioembolism; SUD, stroke of undetermined etiology; IAT, intra-arterial therapy; ICH, intracranial hemorrhage; GP, glycoprotein.

<sup>a</sup> Significant.